Luminal B is a subtype of hormone receptor-positive breast cancer that grows faster and is more aggressive than its close relative, Luminal A. Both subtypes are fueled by estrogen, but Luminal B tumors have higher rates of cell division, tend to be higher grade, and respond less reliably to hormone-blocking therapy alone. About 18% of all hormone receptor-positive breast cancers fall into the Luminal B category.
How Luminal B Is Identified
Breast cancers are classified into molecular subtypes based on which proteins the tumor cells display on their surface and how quickly the cells are dividing. Luminal B tumors are positive for estrogen receptors (ER) or progesterone receptors (PR), and they also show either high levels of HER2 (a growth-promoting protein) or a high Ki-67 index. Ki-67 is a marker of how fast tumor cells are multiplying. A Ki-67 score of 14% or higher is the commonly used cutoff that separates Luminal B from Luminal A.
Because of this, Luminal B actually comes in two variants. One is HER2-negative with high Ki-67, and the other is HER2-positive regardless of Ki-67. The distinction matters for treatment: the HER2-positive variant may benefit from targeted HER2 therapies on top of other treatments. Studies show the two variants can have meaningfully different outcomes, so your oncologist will pay close attention to both markers.
Luminal B tumors also tend to have lower progesterone receptor expression than Luminal A. In practical terms, a pathology report showing ER-positive, low PR, and a Ki-67 above 14% points strongly toward a Luminal B classification.
What Makes Luminal B Different From Luminal A
Luminal A and Luminal B share some of the same estrogen-related gene activity, which is why both are classified as “luminal” (hormone-driven). But the similarities largely end there. Luminal A cancers are typically low grade, slow growing, and carry the best prognosis of any breast cancer subtype. Luminal B tumors are intermediate to high grade with significantly more cell proliferation.
At the genetic level, Luminal B tumors share some gene expression patterns not with Luminal A but with basal-like (triple-negative) breast cancer, particularly genes involved in cell division like MKI67, survivin, and cyclin B1. Luminal B cancers also have more genomic instability and a higher frequency of TP53 mutations, a gene that normally acts as a brake on tumor growth. When TP53 is mutated, that brake is lost. Mutations in the PIK3CA gene, which helps regulate cell growth signaling, are also common.
The clinical difference is straightforward: Luminal A patients generally do well on hormone therapy alone, while Luminal B patients face a higher risk of early relapse if treated with hormone therapy as their only systemic treatment.
Genomic Testing and Risk Scores
If you have an ER-positive breast cancer, your oncologist may order a genomic test like Oncotype DX to help predict recurrence risk and guide treatment decisions. These tests analyze a panel of genes in the tumor and produce a recurrence score. Luminal A cancers typically score around 15 on Oncotype DX, while Luminal B cancers have a median score of 25, with values commonly falling between 19 and 40.
Among Luminal B patients tested with Oncotype DX, roughly one-third score in the high-risk category (above 31) and nearly half land in the intermediate range (18 to 31). These scores help clarify whether chemotherapy is likely to provide a meaningful benefit beyond hormone therapy. There is generally good agreement between genomic tests and the molecular subtype determined by pathology, particularly at the extremes of high and low risk.
Why Hormone Therapy Is Less Effective
One of the defining challenges of Luminal B breast cancer is its relative resistance to endocrine (hormone-blocking) therapy compared to Luminal A. Several factors explain this. Luminal B tumors express lower levels of the estrogen receptor itself, along with lower levels of other luminal-related genes like FOXA1. Because the estrogen receptor signal is weaker to begin with, blocking it has less impact on slowing tumor growth.
In about 15 to 20% of resistant cases, tumor cells find an alternative way to keep dividing that bypasses estrogen signaling entirely. Some cells can even shift from ER-positive to ER-negative over time. Because Luminal B tumors start with lower ER expression, they are more vulnerable to this kind of switch. This is a key reason Luminal B cancers carry a higher risk of developing endocrine resistance than Luminal A cancers, and why additional treatment strategies are often needed.
Treatment Approach
Luminal B breast cancer is typically treated with a combination of hormone therapy and chemotherapy, rather than hormone therapy alone. The added chemotherapy addresses the high proliferation rate that defines the subtype. For the HER2-positive variant, HER2-targeted therapy is added to the regimen.
Interestingly, the two Luminal B variants may respond differently to treatment sequencing. Research has found that HER2-negative Luminal B patients who received chemotherapy before surgery (neoadjuvant chemotherapy) had better outcomes, while HER2-positive Luminal B patients who did not receive neoadjuvant chemotherapy had better prognoses. These differences highlight why treatment plans are tailored to the specific biology of each tumor rather than following a one-size-fits-all approach.
Prognosis and Survival
Luminal B breast cancer has a worse prognosis than Luminal A, but the overall outlook for early-stage luminal breast cancers remains favorable. In a large multicenter study of stage I luminal breast cancers, disease-free survival rates were approximately 97.6% at five years and 91.5% at ten years, with overall survival rates of 99.4% and 98.3% at those same time points.
For patients treated with hormone therapy alone, the risk of relapse was approximately 1% at five years in low-risk populations. When chemotherapy was part of the treatment, five-year disease-free survival was about 95.6%, dropping to 87.8% at ten years. These numbers reflect early-stage disease; more advanced stages carry higher recurrence risk.
The 10-year breast cancer-specific survival rate for the Luminal B subgroup defined by high Ki-67 or HER2 positivity is around 61%, a figure that underscores the more aggressive nature of this subtype compared to Luminal A. However, outcomes vary widely depending on stage at diagnosis, grade, lymph node involvement, and how the tumor responds to treatment. Earlier detection and appropriate combination therapy significantly improve the long-term picture.